Alunbrig scores NICE backing for ALK-positive lung cancer 11th December 2020 Takeda’s Alunbrig (brigatinib) has been recommended by the UK’s National Institute for Health and Care Excellence (NICE) for patients with ALK-positive advanced non-small cell lung cancer (NSCLC). Although ALK-positive NSCLC is rare, it is a particularly resistant disease which mainly affects younger people and non-smokers. Although a number of ALK inhibitors have recently been introduced to this therapy area in recent years, some patients still progress within two to three years of starting treatment. In addition, up to 75% of patients develop brain metastases during the course of their disease.